Pharmacology of the phosphate binder, lanthanum carbonate

Renal Failure

Volumn 33, Issue 2, 2011, Pages 217-224

  Damment, Stephen J P ^a  

^a Shire Pharmaceuticals   (United Kingdom)

Author keywords

chronic kidney disease; hyperphosphatemia; kidney diseases; lanthanum carbonate; phosphate binder

Indexed keywords

ALUMINUM HYDROXIDE; CALCIUM; CALCIUM CARBONATE; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHATE P 32; SEVELAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG POTENCY; FECES; KIDNEY FUNCTION; MALE; MOUSE; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PHOSPHATE URINE LEVEL; PRIORITY JOURNAL; RAT;

ALUMINUM HYDROXIDE; ANIMALS; CALCIUM; CALCIUM CARBONATE; CHELATING AGENTS; DOGS; DRUG EVALUATION, PRECLINICAL; FECES; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; MICE; PHOSPHATES; PHOSPHORUS RADIOISOTOPES; POLYAMINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79951977919     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.552821     Document Type: Article

References (30)

1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-2218. (Pubitemid 39031360)
2. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67(3):1179-1187. (Pubitemid 41623345)
3. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(5):1423-1429.
4. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl. 3):1-201.
5. Finn WF. Phosphorus management in end-stage renal disease. Semin Dial. 2005;18(1):8-12. (Pubitemid 40348269)
6. Shinaberger CS, Greenland S, Kopple JD, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr. 2008;88(6):1511-1518.
7. Hutchison AJ. Improving phosphate-binder therapy as a way forward. Nephrol Dial Transplant. 2004;19(Suppl. 1):i19-i24. (Pubitemid 38455639)
8. Sheikh MS, Maguire JA, Emmett M, et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest. 1989; 83(1):66-73. (Pubitemid 19048406)
9. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 1999;55(1):299-307. (Pubitemid 29004263)
10. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003;42(1):96-107. (Pubitemid 36807658)
11. Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: Calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007;23(12):3167-3175.
12. Shigematsu T. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol. 2008;70(5):404-410.
13. Arenas MD, Rebollo P, Malek T, et al. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. J Nephrol. 2010;23(6):683-692.
14. Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci. 2007;96 (10):2818-2827. (Pubitemid 47597830)
15. Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: A crossover study. Clin Nephrol. 2009;72(4):252-258.
16. Behets GJ, Dams G, Vercauteren SR, et al. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol. 2004;15(8):2219-2228. (Pubitemid 39031361)
17. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2000. Safety pharmacology studies for human pharmaceuticals S7A. http://www.ich.org/fileadmin/Public-Web-Site/ ICH-Products/Guidelines/Safety/S7A/Step4/S7A-Guideline.pdf. Accessed January 21, 2011.
18. Vogel H, Hock F, Maas J, Mayer D. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Berlin: Springer-Verlag; 2006.
19. Nagano N, Miyata S, Obana S, et al. Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant. 2001;16(9):1870-1878. (Pubitemid 32821420)
20. Nagano N, Miyata S, Obana S, et al. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant. 2003;18(10):2014-2023. (Pubitemid 37220306)
21. Behets GJ, D'Haese PC, De Broe ME. Gastrointestinal calcium absorption after ingestion of non calcium containing phosphate binders in a healthy rat model [Abstract FPO1859]. J Am Soc Nephrol. 2009;20:537A.
22. Evans CH. Biochemistry of the Lanthanides. New York: Plenum Press; 1990.
23. Damment SJ, Pennick M. Systemic lanthanum is excreted in the bile of rats. Toxicol Lett. 2007;171:69-77. (Pubitemid 46990669)
24. Kato M, Sugihara J, Nakamura T, Muto Y. Electron microscopic study of the blood-brain barrier in rats with brain edema and encephalopathy due to acute hepatic failure. Gastroenterol Jpn. 1989;24(2):135-142. (Pubitemid 19162222)
25. Xu J, Ling EA. Studies of the ultrastructure and permeability of the blood-brain barrier in the developing corpus callosum in postnatal rat brain using electron dense tracers. J Anat. 1994;184:227-237. (Pubitemid 24114584)
26. Sacchiero R, Berlove D, Brezzani A, Hanus M, Zhorov E, Burke S. Lanthanum deposition in tissues of renal compromised rats fed lanthanum carbonate for 28 days [Abstract FPO658]. J Am Soc Nephrol. 2003;14:205A.
27. Lacour B, Lucas A, Auchere D, Ruellan N, de Serre Patey NM, Drueke TB. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 2005;67(3):1062-1069. (Pubitemid 41623331)
28. Damment SJ, Cox AG, Secker R. Dietary administration in rodent studies distorts the tissue deposition profile of lanthanum carbonate; brain deposition is a contamination artefact? Toxicol Lett. 2009;188(3):223-229.
29. Altmann P, Barnett ME, Finn WF. Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: No adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int. 2007;71(3):252-259. (Pubitemid 46160926)
30. Meyers FH, Jawetz E, Goldfein A. Gastrointestinal drugs. In: Review of Medical Pharmacology. Los Altos, CA: Lange Medical Publications; 1980:325-331.